No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy

Epilepsy Research

Volumn 83, Issue 1, 2009, Pages 44-51

  Lynch, J M ^a,b   Tate, S K ^a,b   Kinirons, P ^c   Weale, M E ^d   Cavalleri, G L ^c   Depondt, C ^e   Murphy, K ^c   O'Rourke, D ^c   Doherty, C P ^f   Shianna, K V ^d   Wood, N W ^a   Sander, J W ^a,b,g   Delanty, N ^c,h   Goldstein, D B ^d   Sisodiya, S M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b EPILEPSY SOCIETY   (United Kingdom)

^c BEAUMONT HOSPITAL   (Ireland)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e ERASME HOSPITAL   (Belgium)

^f ST JAMES S HOSPITAL   (Ireland)

^g STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^h ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Antiepileptic drugs; Association studies in genetics; Levetiracetam; Pharmacogenetics; Synaptic vesicle 2A

Indexed keywords

CARRIER PROTEIN; ETIRACETAM; SYNAPTIC VESICLE PROTEIN 2A; SYNAPTIC VESICLE PROTEIN 2B; SYNAPTIC VESICLE PROTEIN 2C; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG RESPONSE; EPILEPSY; FEMALE; FOCAL EPILEPSY; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTICONVULSANTS; COHORT STUDIES; EPILEPSY; EPILEPSY, TEMPORAL LOBE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; GREAT BRITAIN; HIPPOCAMPUS; HUMANS; IRELAND; MALE; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; PIRACETAM; POLYMORPHISM, GENETIC; SYNAPTIC VESICLES;

EID: 57849143713     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2008.09.003     Document Type: Article

References (18)

1. Ben-Menachem E., and Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41 (2000) 1276-1283
2. Berg A.T., and Kelly M.M. Defining intractability: comparisons among published definitions. Epilepsia 47 (2006) 431-436
3. Botstein D., and Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat. Genet. 33 Suppl. (2003) 228-237
4. Cavalleri G.L., Weale M.E., Shianna K.V., Singh R., Lynch J.M., Grinton B., Szoeke C., Murphy K., Kinirons P., O'Rourke D., Ge D., Depondt C., Claeys K.G., Pandolfo M., Gumbs C., Walley N., Mcnamara J., Mulley J.C., Linney K.N., Sheffield L.J., Radtke R.A., Tate S.K., Chissoe S.L., Gibson R.A., Hosford D., Stanton A., Graves T.D., Hanna M.G., Eriksson K., Kantanen A.M., Kalviainen R., O'Brien T.J., Sander J.W., Duncan J.S., Scheffer I.E., Berkovic S.F., Wood N.W., Doherty C.P., Delanty N., Sisodiya S.M., and Goldstein D.B. Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurol. 6 (2007) 970-980
5. Cereghino J.J., Biton V., bou-Khalil B., Dreifuss F., Gauer L.J., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
6. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., Scheller R.H., Chavkin C., and Bajjalieh S.M. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). PNAS 96 (1999) 15268-15273
7. Depondt C., Yuen A.W., Bell G.S., Mitchell T., Koepp M.J., Duncan J.S., and Sander J.W. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J. Neurol. Neurosurg. Psychiatry 77 (2006) 101-103
8. Ferraro T.N., Dlugos D.J., and Buono R.J. Challenges and opportunities in the application of pharmacogenetics to antiepileptic drug therapy. Pharmacogenomics 7 (2006) 89-103
9. Goldstein D.B., Tate S.K., and Sisodiya S.M. Pharmacogenetics goes genomic. Nat. Rev. Genet. 4 (2003) 937-947
10. Kinirons P., McCarthy M., Doherty C.P., and Delanty N. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam. Seizure 15 (2006) 387-392
11. Kumar S.P., and Smith P.E. Levetiracetam as add-on therapy in generalised epilepsies. Seizure 13 (2004) 475-477
12. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9861-9866
13. Mehta C.R., and Patel N.R. A Fortran Subroutine for Fisher Exact Test on Unordered Rxc Contingency-Tables. Acm Trans. Math. Software 12 (1986) 154
14. O'Brien E., Murphy J., Tyndall A., Atkins N., Mee F., McCarthy G., Staessen J., Cox J., and O'Malley K. Twenty-four-hour ambulatory blood pressure in men and women aged 17 to 80 years: the Allied Irish Bank Study. J. Hypertension 9 (1991) 355-360
15. Purcell S., Cherny S., and Sham P.C. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19 (2003) 149-150
16. Shorvon S.D., Lowenthal A., Janz D., Bielen E., and Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 41 (2000) 1179-1186
17. Weber S., and Beran R.G. A pilot study of compassionate use of Levetiracetam in patients with generalised epilepsy. J. Clin. Neurosci. 11 (2004) 728-731
18. Whitlock M.C. Combining probability from independent tests: the weighted Z-method is superior to Fisher's approach. J. Evol. Biol. 18 (2005) 1368-1373